Surrozen (SRZN) has received a new Buy rating, initiated by LifeSci Capital analyst, Patrick Dolezal.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Dolezal has given his Buy rating due to a combination of factors that highlight Surrozen’s promising potential in the biotechnology sector. The company is pioneering in the development of wnt-targeted therapies, which could significantly disrupt the existing $15 billion anti-VEGF market by not only preventing further damage but also aiming to restore function to damaged retinal tissue. This innovative approach positions Surrozen as a potential leader in treating retinal vascular disorders.
Surrozen’s lead candidate, SZN-8141, is particularly noteworthy as it combines mechanisms from successful therapies and is expected to be evaluated for diabetic macular edema and wet age-related macular degeneration. The asset is considered mechanistically derisked due to proof-of-concept data from Merck’s acquisition of a similar asset, which enhances confidence in its efficacy and safety. Additionally, the company’s financial backing and strategic selection of targets further strengthen its position, making it a compelling investment opportunity.
In another report released on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $32.00 price target.